AMGN

Amgen Inc.

277.19 USD
-0.28 (-0.10%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Amgen Inc. stock is down -11.9% since 30 days ago. The next earnings date is Apr 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 46.34% of the previous 40 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 80% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
27 Feb 20:56 19 Apr, 2024 280.00 CALL 55 762
28 Feb 14:31 15 Mar, 2024 282.50 PUT 50 163
28 Feb 15:17 01 Mar, 2024 277.50 CALL 100 115
28 Feb 15:55 01 Mar, 2024 277.50 CALL 100 115
28 Feb 15:59 16 Aug, 2024 280.00 CALL 75 45
28 Feb 16:38 17 May, 2024 275.00 CALL 18 15
28 Feb 20:27 16 Jan, 2026 150.00 CALL 3 12
28 Feb 20:43 19 Apr, 2024 290.00 PUT 25 1029
28 Feb 20:47 17 May, 2024 275.00 PUT 39 59
28 Feb 20:56 21 Jun, 2024 280.00 CALL 18 1296

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.

  • Goldman Sachs
    Thu Feb 8, 10:32
    buy
    confirm
  • RBC Capital
    Wed Feb 7, 11:48
    buy
    confirm
  • Goldman Sachs
    Wed Feb 7, 08:27
    buy
    confirm
  • Morgan Stanley
    Wed Feb 7, 04:44
    hold
    confirm
  • Oppenheimer
    Thu Feb 1, 12:27
    buy
    confirm